PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-139.60%
Both yoy net incomes decline, with AVXL at -4.23%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
0.49%
D&A growth of 0.49% while AVXL is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
No Data
No Data available this quarter, please select a different quarter.
637.66%
SBC growth well above AVXL's 2.09%. Michael Burry would flag major dilution risk vs. competitor’s approach.
-41.30%
Both reduce yoy usage, with AVXL at -171.42%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-41.30%
Negative yoy usage while AVXL is 222.49%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
No Data
No Data available this quarter, please select a different quarter.
-31.70%
Both yoy CFO lines are negative, with AVXL at -82.04%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Issuance growth of 100.00% while AVXL is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
No Data
No Data available this quarter, please select a different quarter.